Пролонгированный режим комбинированного орального контрацептива: фокус на профилактику воспалительных заболеваний органов малого таза


Цитировать

Полный текст

Аннотация

В статье представлены данные, касающиеся профилактических эффектов комбинированных оральных контрацептивов (КОК) в отношении рисков возникновения воспалительных заболеваний органов малого таза (ВЗОМТ), дополненные современными представлениями о влиянии КОК на состояние цервиковагинального лаважа, зависимости секреции противомикробных пептидов от фазы менструального цикла и приема КОК. Представлены данные метаанализов о снижении рецидивов бактериального вагиноза на фоне приема КОК, а также дано обоснование профилактического действия пролонгированного режима приема Джес® во флекс-картридже в отношении ВЗОМТ у женщин, нуждающихся в контрацепции.

Об авторах

Н И Тапильская

ФГБОУ ВО «Санкт-Петербургский государственный педиатрический медицинский университет» Минздрава России

Email: tapnatalia@yandex.ru
д-р мед. наук, проф. каф. акушерства и гинекологии, проф. каф. онкологии, детской онкологии и лучевой терапии ФГБОУ ВО СПбГПМУ 194100, Россия, Санкт-Петербург, ул. Литовская, д. 2

Р И Глушаков

ФГБОУ ВО «Санкт-Петербургский государственный педиатрический медицинский университет» Минздрава России

канд. мед. наук, доц. каф. фармакологии и доказательной медицины (с курсом клинической фармакологии) ФГБОУ ВО СПбГПМУ 194100, Россия, Санкт-Петербург, ул. Литовская, д. 2

Список литературы

  1. Корхов В.В., Тапильская Н.И. Гестагены в акушерско - гинекологической практике: руководство для врачей. СПб.: СпецЛит, 2005.
  2. Савичева А.М. и др. Инфекционно - воспалительные заболевания в акушерстве и гинекологии. Под ред. Э.К.Айламазяна. М.: ГЭОТАР-Медиа, 2016.
  3. Тапильская Н.И., Карпеев С.А., Кузнецова И.В. Хронический эндометрит - субклиническое воспалительное заболевание органов малого таза // Гинекология. 2014; 16 (1): 104-9.
  4. Abbott D.S, Chin-Smith E.C, Seed P.T et al. Raised trappin2/elafin protein in cervico - vaginal fluid is a potential predictor of cervical shortening and spontaneous preterm birth. PLoS One 2014; 9: e100771.
  5. Andrist L.C, Arias R.D, Nucatola D et al. Women’s and providers’ attitudes toward menstrual suppression with extended use of oral contraceptives. Contraception 2004; 70: 359-63.
  6. Baeten J.M, Nyange P.M, Richardson B.A et al. Hormonal contraception and risk of sexually transmitted disease acquisition: results from a prospective study. Am J Obstet Gynecol 2001; 185 (2): 380-5.
  7. Bradshaw C.S, Brotman R.M. Making inroads into improving treatment of bacterial vaginosis - striving for long - term cure. BMC Infect Dis 2015; 15 (1): 292.
  8. Bradshaw C.S, Vodstrcil L.A, Hocking J.S et al. Recurrence of bacterial vaginosis is significantly associated with posttreatment sexual activities and hormonal contraceptive use. Clin Infect Dis 2013; 56 (6): 777-86.
  9. Burgener A, Rahman S, Ahmad R et al. Comprehensive proteomic study identifies serpin and cystatinantiproteases as novel correlates of HIV-1 resistance in the cervicovaginal mucosa of female sex workers. J Proteome Res 2011; 10: 5139-49.
  10. Burkman R.T. Oral contraceptives: current status. Clin Obstet Gynecol 2001; 44 (1): 62-72.
  11. Calzolari E, Masciangelo R, Milite V, Verteramo R. Bacterial vaginosis and contraceptive methods. Int J Gynecol Obstet 2000; 70 (3): 341-6.
  12. Cauci S, Culhane J.F. Modulation of vaginal immune response among pregnant women with bacterial vaginosis by Trichomonasvaginalis, Chlamydia trachomatis, Neisseria gonorrhoeae, and yeast. Am Journal Obstet Gynecol 2007; 196 (2): 133-e1.
  13. Cicinelli E, Ballini A, Marinaccio M et al. Microbiological findings in endometrial specimen: our experience. Arch Gynecol Obstet 2012; 285 (5): 1325-9.
  14. Cole A.M. Innate host defense of human vaginal and cervical mucosae. Curr Top Microbiol Immunol 2006; 306: 199-230.
  15. Cole A.M, Cole A.L. Antimicrobial polypeptides are key anti-HIV-1 effector molecules of cervicovaginal host defense. Am J Reprod Immunol 2008; 59: 27-34.
  16. Cowling P, Mc Coy D.R, Marshall R.J et al. Bacterial colonization of the nonpregnant uterus: a study of pre - menopausal abdominal hysterectomy specimens. Eur J Clin Microbiol Infect Dis 1992; 11 (2): 204-5.
  17. Dasari S, Pereira L, Reddy A.P et al. Comprehensive proteomic analysis of human cervical - vaginal fluid. J Proteome Res 2007; 6: 1258-68.
  18. Doerflinger S.Y, Throop A.L, Herbst-Kralovetz M.M. Bacteria in the vaginal microbiomealter the innate immune response and barrier properties of the human vaginal epithelia in a species - specific manner. J Infect Dis 2014; 209: 1989-99.
  19. Drannik A.G, Nag K, Sallenave J.M, Rosenthal K.L. Antiviral activity of trappin-2 and elafin in vitro and in vivo against genital herpes. J Virol 2013; 87: 7526-38.
  20. Eschenbach D.A, Harnisch J.P, Holmes K.K. Pathogenesis of acute pelvic inflammatory disease: role of contraception and other risk factors. Am J Obstet Gynecol 1977; 128 (8): 838-50.
  21. Ferrero S, Abbamonte L.H, Giordano M et al. What is the desired menstrual frequency of women without menstruationrelated symptoms? Contraception 2006; 73: 537-41.
  22. Frew L, Makieva S, Mc Kinlay A.T et al. Human cathelicidin production by the cervix. PLoS One 2014; 9: e103434.
  23. Ghosh M. Secreted mucosal antimicrobials in the female reproductive tract that are important to consider for HIV prevention. Am J Reprod Immunol 2014; 71: 575-88.
  24. Ghosh M, Shen Z, Schaefer T.M et al. CCL20/MIP3alpha is a novel anti-HIV-1 molecule of the human female reproductive tract. Am J Reprod Immunol 2009; 62: 60-71.
  25. Grio R, Latino M.A, Leotta E et al. Sexually transmitted diseases and pelvic inflammatory disease. Minerva ginecologica 2004; 56 (2): 141-7.
  26. Guthrie B.L, Introini A, Roxby A.C et al. Depot medroxyprogesterone acetate use is associated with elevated innate immune effector molecules in cervicovaginal secretions of HIV-1-uninfected women. J Acquir Immune Defic Syndr 2015; 69 (1): 1-10.
  27. Hebb J.K, Cohen C.R, Astete S.G et al. Detection of novel organisms associated with salpingitis, by use of 16S rDNA polymerase chain reaction. J Infect Dis 2004; 190 (12): 2109-20.
  28. Holzman C, Leventhal J.M, Qiu H et al. Grp BVS. Factors linked to bacterial vaginosis in nonpregnant women. Am J Public Health 2001; 91 (10): 1664-70.
  29. Horne A.W, Stock S.J, King A.E. Innate immunity and disorders of the female reproductive tract. Reproduction 2008; 135: 739-49.
  30. Huber J.C, Bentz E.K, Ott J, Tempfer C.B. Non - contraceptive benefits of oral contraceptives. Exp Opin Pharmacother 2008; 9 (13): 2317-25.
  31. Kaunitz A.M. Oral contraceptive health benefits: perception versus reality. Contraception 1999; 59 (Suppl. 1): 29S-33S.
  32. Kawano Y, Nakamura S, Nasu K et al. Expression and regulation of thrombospondin-1 by human endometrial stromal cells. Fertil Steril 2005; 83: 1056-9.
  33. Klipping C, Duijkers I, Fortier M.P et al. Long - term tolerability of ethinylestradiol 20 μg/drospirenone 3 mg in a flexible extended regimen: results from a randomised, controlled, multicentre study. J Fam Plann Reprod Health Care 2012; 38: 84-93.
  34. Klipping C et al. Contraceptive efficacy and tolerability of ethinylestradiol 20μg/drospirenone 3 mg in a flexible extended regimen: an open - label, multicentre, randomised, controlled study. J Fam Plann Reprod Health Care 2012; 38: 73-83.
  35. Klotman M.E, Chang T.L. Defensins in innate antiviral immunity. Nat Rev Immunol 2006; 6: 447-56.
  36. Legro R.S, Pauli J.G, Kunselman A.R et al. Effects of continuous versus cyclical oral contraception: a randomized controlled trial. J Clin Endocrinol Metab 2008; 93: 420-9.
  37. Lourenco A.G, Komesu M.C, Machado A.A et al. Semen lactoferrin promotes CCL20 production by epithelial cells: involvement in HIV transmission. World J Virol 2014; 3: 11-7.
  38. Michel K.G, Huijbregts R.P, Gleason J.L et al. Effect of hormonal contraception on the function of plasmacytoid dendritic cells and distribution of immune cell populations in the female reproductive tract. J Acquir Immune Defic Syndr 2015; 68 (5): 511-8.
  39. Mоller B.R, Kristiansen F.V, Thorsen P et al. Sterility of the uterine cavity. Acta Obstet Gynecol Scand 1995; 74 (3): 216-9.
  40. Morrison C, Fichorova R.N, Mauck C et al. Cervical inflammation and immunity associated with hormonal contraception, pregnancy, and HIV-1 seroconversion. J Acquir Immune Defic Syndr 2014; 66 (2):109-17.
  41. Okumura K, Ikeda S, Ogawa H. Host defense (antimicrobial) peptide, human beta - defensin-3, improves the function of the epithelial tight - junction barrier in human keratinocytes. J Invest Dermatol 2014; 134: 2163-73.
  42. Peterson H.B, Lee N.C. The health effects of oral contraceptives: Misperceptions, controversies, and continuing good news. Clin Obstet Gynecol 1989; 32: 339-55.
  43. Riggs M, Klebanoff M, Nansel T et al. Longitudinal association between hormonal contraceptives and bacterial vaginosis in women of reproductive age. Sex Transm Dis 2007; 34 (12): 954-9.
  44. Rifkin S.B, Smith M.R, Brotman R.M et al. Hormonal contraception and risk of bacterial vaginosis diagnosis in an observational study of women attending STD clinics in Baltimore. MD Contracept 2009; 80 (1): 63-7.
  45. Romero R, Hassan S.S, Gajer P et al. The composition and stability of the vaginal microbiota of normal pregnant women is different from that of non - pregnant women. Microbiome 2014; 2: 4.
  46. Ruan X, Mueck A.O. Oral contraception for women of middle age. Maturitas 2015; 82 (3): 266-70.
  47. Rubin G.L, Ory H.W, Layde P.M. Oral contraceptives and pelvic inflammatory disease. Am J Obstet Gynecol 1982; 144 (6): 630-5.
  48. Schindler A.E. Non - Contraceptive Benefits of Oral Hormonal Contraceptives. Int J Endocrinol Metab 2013; 11 (1): 41-7.
  49. Sharma H, Tal R, Clark N.A, Segars J.H. Microbiota and pelvic inflammatory disease. Semin Reprod Med 2014; 32: 43-9.
  50. Swidsinski A, Verstraelen H, Loening-Baucke V et al. Presence of a polymicrobial endometrial biofilm in patients with bacterial vaginosis. PLoS One 2013; 8 (1): e53997.
  51. Tibaldi C, Cappello N, Latino M.A et al. Vaginal and endocervical microorganisms in symptomatic and asymptomatic non - pregnant females: risk factors and rates of occurrence. Clin Microbiol Infect 2009; 15 (7): 670-9.
  52. Valore E.V, Park C.H, Igreti S.L, Ganz T. Antimicrobial components of vaginal fluid. Am J Obstet Gynecol 2002; 187: 561-8.
  53. Van de Wijgert J.H, Verwijs M.C, Turner A.N, Morrison C.S. Hormonal contraception decreases bacterial vaginosis but oral contraception may increase candidiasis: implications for HIV transmission. AIDS 2013; 27 (13): 2141-53.
  54. Vodstrcil L.A, Hocking J.S, Law M et al. Hormonal contraception is associated with a reduced risk of bacterial vaginosis: a systematic review and meta - analysis. PLoS One 2013; 8 (9): e73055.
  55. Wira C.R, Fahey J.V, Ghosh M et al. Sex hormone regulation of innate immunity in the female reproductive tract: the role of epithelial cells in balancing reproductive potential with protection against sexually transmitted pathogens. Am J Reprod Immunol 2010; 63: 544-65.
  56. Wira C.R, Veronese F. Hormone regulation of the mucosal environment in the reproductive tract and the prevention of HIV infection. Am J Reprod Immunol 2014; 71: 487-9.
  57. Wølner-Hanssen P, Eschenbach D.A, Paavonen J et al. Decreased risk of symptomatic chlamydial pelvic inflammatory disease associated with oral contraceptive use. JAMA 1990; 263 (1): 54-9.
  58. Yarbrough V.L, Winkle S, Herbst-Kralovetz M.M. Antimicrobial peptides in the female reproductive tract: a critical component of the mucosal immune barrier with physiological and clinical implications. Human Reproduction Update 2015; 21 (3): 353-77.

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© ООО "Консилиум Медикум", 2017

Creative Commons License
Эта статья доступна по лицензии Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).